| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 用于治疗或预防注意力缺陷多动障碍(ADHD)的二胺氧化酶 | CN201380020361.6 | 2013-04-18 | CN104284672A | 2015-01-14 | C·德鲁里乌; J·J·德鲁里乌 |
| 本发明涉及用于治疗和预防注意力缺陷多动障碍(ADHD)的二胺氧化酶。 | ||||||
| 2 | 用于治疗或预防与高组胺水平相关的涉及疼痛增加的疾病的含二胺氧化酶的局部组合物 | CN201280013856.1 | 2012-03-15 | CN103476422A | 2013-12-25 | C·德鲁里乌; J·J·德鲁里乌 |
| 本发明涉及一种包含DAO的药物组合物、化妆品组合物或护肤品组合物，所述组合物用于治疗或预防与血液中高水平组胺相关的涉及疼痛增加的疾病或病理状况，其特征在于所述组合物的施用是局部的。 | ||||||
| 3 | 编码N-甲基腐胺氧化酶之核酸及其应用 | CN201510098497.X | 2007-06-19 | CN104894158A | 2015-09-09 | 乔纳森·E·佩奇; 刘恩武 |
| 本发明提供编码N-甲基腐胺氧化酶(MPO)的基因及其核酸建构物，包括独自调控MPO表达的方法，或与调控其它生物碱合成基因相结合调控MPO表达以调节植物和宿主细胞中生物碱的生成。MPO基因或其片段因而有助于减少或增加植物吡咯烷类生物碱或托烷类生物碱的生成和在宿主细胞内生产MPO酶。 | ||||||
| 4 | 含有二胺氧化酶的功能性食品及其用途 | CN201280013452.2 | 2012-03-15 | CN103442595A | 2013-12-11 | C·德鲁里乌; J·J·德鲁里乌 |
| 本发明涉及含DAO的功能性食品及其用于预防或治疗与血液中高水平的组胺相关的疾病或病理状况的用途，特别用于治疗或预防偏头痛、慢性疲劳、纤维肌痛、脊椎炎和由肌肉挛缩引起的疼痛的用途。 | ||||||
| 5 | 编码N‑甲基腐胺氧化酶之核酸及其应用 | CN200780030894.7 | 2007-06-19 | CN102083987B | 2017-04-26 | 乔纳森·E·佩奇; 刘恩武 |
| 本发明提供编码N‑甲基腐胺氧化酶(MPO)的基因及其核酸建构物，包括独自调控MPO表达的方法，或与调控其它生物碱合成基因相结合调控MPO表达以调节植物和宿主细胞中生物碱的生成。MPO基因或其片段因而有助于减少或增加植物吡咯烷类生物碱或托烷类生物碱的生成和在宿主细胞内生产MPO酶。 | ||||||
| 6 | 编码N-甲基腐胺氧化酶之核酸及其应用 | CN200780030894.7 | 2007-06-19 | CN102083987A | 2011-06-01 | 乔纳森·E·佩奇; 刘恩武 |
| 本发明提供编码N-甲基腐胺氧化酶(MPO)的基因及其核酸建构物，包括独自调控MPO表达的方法，或与调控其它生物碱合成基因相结合调控MPO表达以调节植物和宿主细胞中生物碱的生成。MPO基因或其片段因而有助于减少或增加植物吡咯烷类生物碱或托烷类生物碱的生成和在宿主细胞内生产MPO酶。 | ||||||
| 7 | 含二氨基氧化酶的药物组合物 | CN200580022791.7 | 2005-07-06 | CN1980689A | 2007-06-13 | 阿尔贝特·米斯比希勒; 弗朗茨·佳博尔; 赫维希·赖希尔 |
| 本发明涉及包含二氨基氧化酶的药物组合物、食物补充剂－组合物和美容组合物，以及它们的用途。 | ||||||
| 8 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF COLITIS IN INFANTS | US16375776 | 2019-04-04 | US20190230970A1 | 2019-08-01 | Adam Hanna |
| This disclosure describes compositions and methods for preventing and/or treating necrotizing enterocolitis (NEC) and preventing loss of intestinal integrity and/or improving intestinal integrity in neonatal subjects. Compositions useful in the methods of the disclosure comprise diamine oxidase (DAO) which can be from any source and formulated for systemic administration. | ||||||
| 9 | FUNCTIONAL FOODS COMPRISING DIAMINE OXIDASE AND USES THEREOF | US15488604 | 2017-04-17 | US20170224784A1 | 2017-08-10 | Carlos DUELO RIU; Juan José Duelo Riu |
| The present invention relates to functional foods comprising DAO and their use for the prevention or treatment of diseases or pathological conditions associated with high levels of histamine in blood, in particular for the prevention or treatment of migraine, chronic fatigue, fibromyalgia, spondylitis and pain caused by muscle contractures. | ||||||
| 10 | Diaminooxidase-containing pharmaceutical compositions | US12862379 | 2010-08-24 | US08716244B2 | 2014-05-06 | Albert Missbichler; Franz Gabor; Herwig Reichl |
| The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof. | ||||||
| 11 | Di-amino oxidase-containing pharmaceutical composition | JP2007519799 | 2005-07-06 | JP2008505869A | 2008-02-28 | アルベルト・ミスビヒラー; フランツ・ガボール; ヘアヴィッヒ・ライヒル |
| 本発明は、ジアミノオキシダーゼを含有する、医薬組成物、栄養補助食品用組成物および化粧品用組成物、ならびにその使用に関する。 | ||||||
| 12 | Di-amino oxidase-containing pharmaceutical composition | JP2007519799 | 2005-07-06 | JP4959558B2 | 2012-06-27 | アルベルト・ミスビヒラー; フランツ・ガボール; ヘアヴィッヒ・ライヒル |
| 13 | TOPICAL COMPOSITIONS COMPRISING DIAMINOOXIDASE FOR THE TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH HIGH HISTAMINE LEVELS WHICH INVOLVE AN INCREASE IN PAIN | EP12711461.9 | 2012-03-15 | EP2686005B1 | 2018-06-27 | DUELO RIU, Carlos; DUELO RIU, Juan José |
| The present invention relates to a pharmaceutical, cosmetic or dermo-cosmetic composition that comprises DAO, for use in the prevention or treatment of diseases or pathological conditions associated with high levels of histamine in blood which involve an increase in pain, characterised in that the application of the composition is topical. | ||||||
| 14 | Regulating alkaloids | US14822105 | 2015-08-10 | US09994860B2 | 2018-06-12 | Takashi Hashimoto; Akira Kato |
| MPO1 and MPO2 can be regulated for either decreasing or increasing alkaloid levels in plants, in particular in Nicotiana plants. In particular, suppressing or overexpressing one or more of MPO1 and MPO2 may be used to decrease or increase nicotine and nicotinic alkaloid levels in tobacco plants. Suppression or overexpression of one or more of MPO1 and MPO2 may be used in combination with modification of expression of other genes encoding enzymes on the nicotinic alkaloid biosynthetic pathway such as A622, NBB1, PMT, and QPT. | ||||||
| 15 | Diaminooxidase-containing pharmaceutical compositions | US14245358 | 2014-04-04 | US09364437B2 | 2016-06-14 | Albert Missbichler; Franz Gabor; Herwig Reichl |
| The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof. | ||||||
| 16 | REGULATING ALKALOIDS | US14820455 | 2015-08-06 | US20160032299A1 | 2016-02-04 | Takashi HASHIMOTO; Akira Kato |
| MPO1 and MPO2 can be regulated for either decreasing or increasing alkaloid levels in plants, in particular in Nicotiana plants. In particular, suppressing or overexpressing one or more of MPO1 and MPO2 may be used to decrease or increase nicotine and nicotinic alkaloid levels in tobacco plants. Suppression or overexpression of one or more of MPO1 and MPO2 may be used in combination with modification of expression of other genes encoding enzymes on the nicotinic alkaloid biosynthetic pathway such as A622, NBB1, PMT, and QPT. | ||||||
| 17 | DIAMINOOXIDASE-CONTAINING PHARMACEUTICAL COMPOSITIONS | US14245358 | 2014-04-04 | US20140220148A1 | 2014-08-07 | Albert MISSBICHLER; Franz GABOR; Herwig REICHL |
| The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof. | ||||||
| 18 | FUNCTIONAL FOODS COMPRISING DIAMINE OXIDASE AND USES THEREOF | US14005072 | 2012-03-15 | US20130344137A1 | 2013-12-26 | Carlos Duelo Riu; Juan José Duelo Riu |
| The present invention relates to functional foods comprising DAO and their use for the prevention or treatment of diseases or pathological conditions associated with high levels of histamine in blood, in particular for the prevention or treatment of migraine, chronic fatigue, fibromyalgia, spondylitis and pain caused by muscle contractures. | ||||||
| 19 | NUCLEIC ACID ENCODING N-METHYLPUTRESCINE OXIDASE AND USES THEREOF | US13774933 | 2013-02-22 | US20130309749A1 | 2013-11-21 | Jonathan E. Page; Enwu Liu |
| The gene encoding N-methylputrescine oxidase (MPO) and constructs comprising such DNA are provided, including methods of regulating MPO expression independently or with other alkaloid biosynthesis genes to modulate alkaloid production in plants and host cells. MPO genes or fragments thereof are useful for reducing pyrrolidine or tropane alkaloid production in plants, for increasing pyrrolidine or tropane alkaloid production in plants, and for producing an MPO enzyme in host cells. | ||||||
| 20 | DIAMINE OXIDASE FOR USE IN THE TREATMENT OR PREVENTION OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | EP13726296.0 | 2013-04-18 | EP2844277A1 | 2015-03-11 | DUELO RIU, Carlos; DUELO RIU, Juan José |
| The present invention refers to diamine oxidase for use in the treatment or prevention of attention deficit hyperactivity disorder (ADHD). | ||||||
QQ群二维码
意见反馈
意见反馈